According to GlobalData’s medical device pipeline database, 20 Hematology Reagents devices are in various stages of development globally. GlobalData’s report Hematology Reagents provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, five are in active development, while the remaining 15 are in an inactive stage of development. There are one products in the early stages of development, and the remaining four are in the late stages of development.
Hematology reagents are the substances or chemicals intended to perform qualitative and/or quantitative analyses of the morphology of the blood, its components, and blood-forming tissues. The reagents used for blood cell counts, coagulation testing, other hematology tests, control, and calibration are included under this segment. Hematology reagents are used in tests of the sequential process by which the multiple factors of the blood interact in a blood sample, resulting in the formation of an insoluble fibrin clot (coagulation). This segment comprises of Hematology Analyzer Reagents, Hemoglobin Testing Reagents, Microscopy Testing Reagents and Other hematology reagents.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Hematology Reagents pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Hematology Reagents devices. Overall, most of these Hematology Reagents pipeline devices are being developed by private entities.
Key players involved in the active development of Hematology Reagents include Alba Bioscience, AliveDx Suisse, Streck, University of California Los Angeles, Cellphire, Children's Hospital of Philadelphia, CPSI Biotech and Grifols.
For a complete picture of the developmental pipeline for Hematology Reagents devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
